DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 207 filers reported holding DENALI THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.17 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $240,949 | +13.7% | 8,165 | -11.3% | 0.00% | – |
Q1 2023 | $211,991 | -71.0% | 9,201 | -59.4% | 0.00% | -100.0% |
Q1 2022 | $730,000 | -68.3% | 22,686 | -56.1% | 0.00% | -75.0% |
Q4 2021 | $2,304,000 | -44.3% | 51,667 | -37.0% | 0.00% | -50.0% |
Q3 2021 | $4,139,000 | -33.4% | 82,049 | +3.5% | 0.01% | -27.3% |
Q2 2021 | $6,219,000 | +25.7% | 79,284 | -8.5% | 0.01% | +37.5% |
Q1 2021 | $4,946,000 | -7.5% | 86,624 | +35.6% | 0.01% | -11.1% |
Q4 2020 | $5,349,000 | +191.3% | 63,867 | +24.6% | 0.01% | +200.0% |
Q3 2020 | $1,836,000 | +163.0% | 51,247 | +77.5% | 0.00% | +200.0% |
Q2 2020 | $698,000 | +48.5% | 28,877 | +7.6% | 0.00% | 0.0% |
Q1 2020 | $470,000 | -45.2% | 26,830 | -45.5% | 0.00% | 0.0% |
Q4 2019 | $857,000 | -18.9% | 49,205 | -28.7% | 0.00% | 0.0% |
Q3 2019 | $1,057,000 | +391.6% | 68,994 | +566.9% | 0.00% | – |
Q2 2019 | $215,000 | – | 10,346 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Crestline Management, LP | 7,705,039 | $343,645,000 | 25.68% |
Casdin Capital, LLC | 1,500,000 | $66,900,000 | 1.89% |
Flagship Pioneering Inc. | 2,619,968 | $116,851,000 | 1.81% |
SECTORAL ASSET MANAGEMENT INC | 189,600 | $8,456,000 | 1.27% |
Integral Health Asset Management, LLC | 100,000 | $4,460,000 | 1.23% |
Temasek Holdings (Private) Ltd | 5,369,487 | $239,479,000 | 0.86% |
Goldstream Capital Management Ltd | 78,418 | $3,497,000 | 0.86% |
Yiheng Capital Management, L.P. | 335,184 | $14,949,000 | 0.76% |
GILDER GAGNON HOWE & CO LLC | 2,900,114 | $129,345,000 | 0.74% |
Artal Group S.A. | 600,000 | $26,760,000 | 0.73% |